Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies.
Kimihiro Nagatani, Hiroshi Nawashiro, Satoru Takeuchi, Satoshi Tomura, Naoki Otani, Hideo Osada, Kojiro Wada, Hiroshi Katoh, Nobusuke Tsuzuki, Kentaro Mori · Medical gas research · 2013
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 38 patients with acute cerebral infarction, analysis of urine sampling and plain chest X-rays showed no indications of pulmonary or urinary tract infection induced by the administration of the H₂ -enriched intravenous solution. These findings add human evidence supporting molecular hydrogen's therapeutic potential for stroke recovery.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 38 patients with acute cerebral infarction. Analysis of urine sampling and plain chest X-rays showed no indications of pulmonary or urinary tract infection induced by the administration of the H₂ -enriched intravenous solution.
What the Researchers Studied
The researchers studied 38 patients with acute cerebral infarction. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
All patients received intravenous H₂ -enriched glucose-electrolyte solution in addition to edaravone immediately after the diagnosis of acute ischemic stroke. For all patients, intravenous edaravone (a 30 mg Edaravone Kit) was given twice a day (every 12 h), and H₂ -enriched intravenous solutions (200 ml) were added at the speed of 200 ml/h twice a day (every 12 h). Acute stroke patients within 3 h of onset received intravenous t-PA treatment (0.6 mg/kg), and those patients receiving t-PA had to commence the administration of H₂ -enriched intravenous solution and edaravone before or at the same time that the t-PA was infused. Analysis of urine sampling and plain chest X-rays showed no indications of pulmonary or urinary tract infection induced by the administration of the H₂ -enriched intravenous solution. The authors concluded that data from the current study indicate that an H₂-enriched intravenous solution is safe for patients with acute cerebral infarction, including patients treated with t-PA.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for stroke recovery and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was 38 patients with acute cerebral infarction. The reported sample size was 38.
Limitations and Safety
Reported limitations: The researchers are currently organizing a new study to address these limitations.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.